The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems
Author:
- 1 February 2017
- journal article
- Published by Elsevier in Value in Health
- Vol. 20 (2) , 278-282
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?Health Economics, 2014
- Insurance and Incentives for Medical InnovationForum for Health Economics and Policy, 2006